Alzheimer's disease: time to focus on the brain, not just molecules

<span class="paragraphSection">One of the biggest drivers for development of targeted treatments for neurodegenerative diseases has come from a better understanding of the molecular pathology. In Alzheimer’s disease, the impetus has been seismic over the last three decades, with a host of findings implicating amyloid or tau as key molecules involved in the process of brain degeneration (<a href="#aww353-B1" class="reflinks">Ballatore <span style="font-style:italic;">et al.</span>, 2007</a>; <a href="#aww353-B2" class="reflinks">Braak and Del Tredici, 2015</a>; <a href="#aww353-B13" class="reflinks">Selkoe and Hardy, 2016</a>). As a result of this pioneering work, there have been intensive efforts both to image amyloid and tau <span style="font-style:italic;">in vivo</span> (<a href="#aww353-B3" class="reflinks">Brosch <span style="font-style:italic;">et al.</span>, 2016</a>; <a href="#aww353-B15" class="reflinks">Thal and Vandenberghe, 2016</a>; <a href="#aww353-B16" class="reflinks">Villemagne, 2016</a>) and to develop therapies aimed at these molecular targets (<a href="#aww353-B5" class="reflinks">Godyń <span style="font-style:italic;">et al.</span>, 2016</a>).</span>

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2k8kYfK
via IFTTT